201 related articles for article (PubMed ID: 37869283)
1. Quantitative evaluation of Kaiser score in diagnosing breast dynamic contrast-enhanced magnetic resonance imaging for patients with high-grade background parenchymal enhancement.
Wang H; Gao L; Chen X; Wang SJ
Quant Imaging Med Surg; 2023 Oct; 13(10):6384-6394. PubMed ID: 37869283
[TBL] [Abstract][Full Text] [Related]
2. High-temporal resolution DCE-MRI improves assessment of intra- and peri-breast lesions categorized as BI-RADS 4.
Liu Y; Wang S; Qu J; Tang R; Wang C; Xiao F; Pang P; Sun Z; Xu M; Li J
BMC Med Imaging; 2023 Apr; 23(1):58. PubMed ID: 37076817
[TBL] [Abstract][Full Text] [Related]
3. [Kaiser score for diagnosis of breast lesions presenting as non-mass enhancement on MRI].
Zhang B; Feng L; Wang L; Chen X; Li X; Yang Q
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Apr; 40(4):562-566. PubMed ID: 32895136
[TBL] [Abstract][Full Text] [Related]
4. The value of DCE- MRI of the breast as a diagnostic tool in assessing amorphous calcifications in screening mammography.
Wang S; Wang H; Li Y; Lou J; Zou Q; Jiang Y; Wu F; Tang Y; Wang S
Front Oncol; 2023; 13():1151500. PubMed ID: 37182168
[TBL] [Abstract][Full Text] [Related]
5. Radiomic analysis of HTR-DCE MR sequences improves diagnostic performance compared to BI-RADS analysis of breast MR lesions.
Perre SV; Duron L; Milon A; Bekhouche A; Balvay D; Cornelis FH; Fournier L; Thomassin-Naggara I
Eur Radiol; 2021 Jul; 31(7):4848-4859. PubMed ID: 33404696
[TBL] [Abstract][Full Text] [Related]
6. The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams.
Milos RI; Pipan F; Kalovidouri A; Clauser P; Kapetas P; Bernathova M; Helbich TH; Baltzer PAT
Eur Radiol; 2020 Nov; 30(11):6052-6061. PubMed ID: 32504098
[TBL] [Abstract][Full Text] [Related]
7. Value of breast MRI omics features and clinical characteristics in Breast Imaging Reporting and Data System (BI-RADS) category 4 breast lesions: an analysis of radiomics-based diagnosis.
Cui Q; Sun L; Zhang Y; Zhao Z; Li S; Liu Y; Ge H; Qin D; Zhao Y
Ann Transl Med; 2021 Nov; 9(22):1677. PubMed ID: 34988186
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric MRI model with dynamic contrast-enhanced and diffusion-weighted imaging enables breast cancer diagnosis with high accuracy.
Zhang M; Horvat JV; Bernard-Davila B; Marino MA; Leithner D; Ochoa-Albiztegui RE; Helbich TH; Morris EA; Thakur S; Pinker K
J Magn Reson Imaging; 2019 Mar; 49(3):864-874. PubMed ID: 30375702
[TBL] [Abstract][Full Text] [Related]
9. Contrast-enhanced MR imaging in patients with BI-RADS 3-5 microcalcifications.
Cilotti A; Iacconi C; Marini C; Moretti M; Mazzotta D; Traino C; Naccarato AG; Piagneri V; Giaconi C; Bevilacqua G; Bartolozzi C
Radiol Med; 2007 Mar; 112(2):272-86. PubMed ID: 17361370
[TBL] [Abstract][Full Text] [Related]
10. Quantitative DWI implemented after DCE-MRI yields increased specificity for BI-RADS 3 and 4 breast lesions.
Dijkstra H; Dorrius MD; Wielema M; Pijnappel RM; Oudkerk M; Sijens PE
J Magn Reson Imaging; 2016 Dec; 44(6):1642-1649. PubMed ID: 27273694
[TBL] [Abstract][Full Text] [Related]
11. A Comparative Assessment of MR BI-RADS 4 Breast Lesions With Kaiser Score and Apparent Diffusion Coefficient Value.
Meng L; Zhao X; Lu L; Xing Q; Wang K; Guo Y; Shang H; Chen Y; Huang M; Sun Y; Zhang X
Front Oncol; 2021; 11():779642. PubMed ID: 34926290
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the role of dynamic contrast-enhanced MR imaging for patients with BI-RADS 3-4 microcalcifications.
Jiang Y; Lou J; Wang S; Zhao Y; Wang C; Wang D
PLoS One; 2014; 9(6):e99669. PubMed ID: 24927476
[TBL] [Abstract][Full Text] [Related]
13. Dynamic contrast-enhanced MR imaging in screening detected microcalcification lesions of the breast: is there any value?
Uematsu T; Yuen S; Kasami M; Uchida Y
Breast Cancer Res Treat; 2007 Jul; 103(3):269-81. PubMed ID: 17063274
[TBL] [Abstract][Full Text] [Related]
14. Impact of background parenchymal enhancement levels on the diagnosis of contrast-enhanced digital mammography in evaluations of breast cancer: comparison with contrast-enhanced breast MRI.
Yuen S; Monzawa S; Gose A; Yanai S; Yata Y; Matsumoto H; Ichinose Y; Tashiro T; Yamagami K
Breast Cancer; 2022 Jul; 29(4):677-687. PubMed ID: 35220511
[TBL] [Abstract][Full Text] [Related]
15. Characteristics, Malignancy Rate, and Follow-up of BI-RADS Category 3 Lesions Identified at Breast MR Imaging: Implications for MR Image Interpretation and Management.
Chikarmane SA; Birdwell RL; Poole PS; Sippo DA; Giess CS
Radiology; 2016 Sep; 280(3):707-15. PubMed ID: 27089027
[TBL] [Abstract][Full Text] [Related]
16. The value of MRI for downgrading of breast suspicious lesions detected on ultrasound.
Xie Z; Xu W; Zhang H; Li L; An Y; Mao G
BMC Med Imaging; 2023 Jun; 23(1):72. PubMed ID: 37271827
[TBL] [Abstract][Full Text] [Related]
17. Revisiting Nonmass Enhancement in Breast MRI: Analysis of Outcomes and Follow-Up Using the Updated BI-RADS Atlas.
Chikarmane SA; Michaels AY; Giess CS
AJR Am J Roentgenol; 2017 Nov; 209(5):1178-1184. PubMed ID: 28834447
[TBL] [Abstract][Full Text] [Related]
18. The value of noncontrast MRI in evaluating breast imaging reporting and data system category 0 lesions on digital mammograms.
Zhang R; Xu M; Zhou C; Ding X; Lu H; Ge M; Du L; Bu Y
Quant Imaging Med Surg; 2022 Aug; 12(8):4069-4080. PubMed ID: 35919041
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of initial enhancement analysis using ultra-fast dynamic contrast-enhanced MRI for breast lesions.
Goto M; Sakai K; Yokota H; Kiba M; Yoshida M; Imai H; Weiland E; Yokota I; Yamada K
Eur Radiol; 2019 Mar; 29(3):1164-1174. PubMed ID: 30088064
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
